Domestic experience of prevention and treatment of skin toxicity in patients with metastatic colorectal cancer receiving inhibitors of EGFR: the example of using of panitumumab

The results of the first national experience of skin toxicity correction in patients with metastatic colorectal cancer (mCRC) receiving EGRF-inhibitors shown on the example of using of Panitumumab. The collection and evaluation of the data were produced in the framework of the project of the working group on maintenance therapy of Russian society of clinical oncologists and chemotherapeutists (RUSSCO) to develop recommendations for the prevention and treatment of dermatological toxicity in patients receiving EGFR-inhibitors. The project involved 10 centers in Russia.  In 58 patients receiving Panitumumab, the efficacy of prophylactic medication and symptomatic treatment of clinical manifestations of dermatological toxicity using available remedies was evaluated. The results confirm the effectiveness of preventive therapy. Optimal correction schemes of various manifestations of dermal toxicity were developed depending on the clinical manifestations and severity.

1. Elez 2008, Bosch 2008, Lacouture ME. Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat Rev Cancer. 2006; 6: 803-812.

2. Perez-Soler R, Saltz L. Cutaneous adverse effects with HER1 / EGFR-targeted agents:

3. is there a silver lining? J Clin Oncol. 2005; 23: 5235-5246.

4. Segaert S & Van Cutsem E. Ann Oncol 2005;16:1425-33.

5. Hassel JC. Onkologie 2010.

6. Giusti RM et al. Clin Cancer Res. 2008;14:1296-302.

7. Douillard J, Siena S, Tabernero J, et al. Final skin toxicity (ST) and patient reported outcomes (PRO) results from PRIME: a randomized phase 3 study of panitumumab (pmab) + FOLFOX4 (CT) for 1st line metastatic colorectal cancer (mCRC). J Clin Oncol 2012;30 (Suppl 4):531 and poster.

8. Price TJ, Sobrero AF, Wilson G, et al. Randomized, open-label, phase III study of panitumumab with FOLFIRI versus FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer (mCRC): Efficacy by skin toxicity. J Clin Oncol 2010;28 (15S): 3529.

9. Van Cutsem E, Peeters M, Siena S, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol. 2007;25 (13):1658-1664.

10. Saltz LB, Meropol NJ, Loehrer PJ, Sr, Needle MN, Kopit J, Mayer RJ. Phase ii trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol. 2004;22:1201-8. doi: 10.1200 / JCO.2004.10.182.

11. Jonker DJ, O’Callaghan CJ, Karapetis CS, et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med. 2007;357:2040-8. doi: 10.1056 / NEJMoa071834.

12. Perez — Soler R. Can rash associated with

13. her1 / egfr inhibition be used as a marker of treatment outcome? Oncology (Williston Park) 2003.

14. Jatoi A, Rowland K, Sloan JA, et al. Tetracycline to prevent epidermal growth factor receptor inhibitor – induced skin rashes: results of a placebo-controlled trial from the North Central Cancer Treatment Group (N03CB) Cancer. 2008;113:847-53. doi: 10.1002 / cncr.23621.

15. N. Mittmann, PhD, S. J. Seung, BSc. Rash rates with egfr inhibitors: meta-analysis, Curr Oncol. 2011 April; 18 (2): e54 — e63. PMCID: PMC3070712.

16. Segaert S et al. J Dtsch Dermatol Ges 2005; 3:599-606.

17. Perez-Soler R et al. Oncologist 2005; 10:345-56.

18. Lynch TJ et al. Oncologist 2007; 12:610-21.

19. Melosky B et al. Oncologist 2009; 16:16-26.

20. Scope A et al. J Clin Oncol 2007; 25:5390-6.

21. Jatoi et al. Cancer 2008; 113:847-53.

22. Segaert S, Van Cutsem E. Ann Oncol 2005; 16:1425-33.

23. Robert C et al. Lancet Oncol 2005; 6:491-500.

24. Guillot B, Bessis D. Ann Dermatol Venerol 2006; 133:1017-20.

25. Gutzmer et al. Hautarzt 2006; 57:509-13.

26. Панитумумаб в терапии метастатического колоректального рака: данные клинических исследований, проблема кожной токсичности / Е. В. Артамонова // Современная онкология. — 2010. — Т.12, № 3. — С.65-70.

27. Lacouture ME, Mitchell EP, Piperdi B et al. Skin Toxicity Evaluation Protocol With Panitumumab (STEPP), a Phase II, Open-Label, Randomized Trial Evaluating the Impact of a Pre-Emptive Skin Treatment Regimen on Skin Toxicities and Quality of Life in Patients With Metastatic Colorectal Cancer / published online ahead of print at www.jco.org on February 8, 2010.

28. NCI-CTCAE V.4.0. Available at: http://ctep.cancer.gov